Screener
Amneal Pharmaceuticals, Inc. AMRX Specialty — Acquisition costs
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:BusinessCombinationAcquisitionRelatedCosts.
The source filing: Amneal Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 5:19 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001723128-26-000031
| Three Months Ended June 30, 2026 | Affordable Medicines (1) | Specialty | Av KARE | Corporateand Other | Total Company |
|---|---|---|---|---|---|
| Selling, general and administrative | 42,367 | 40,095 | 16,913 | 49,347 | 148,722 |
| Research and development | 33,023 | 5,994 | — | — | 39,017 |
| Intellectual property legal development expenses | 2,002 | 85 | — | — | 2,087 |
| Acquisition costs | — | — | — | 7,600 | 7,600 |
| Restructuring and other charges | — | — | — | 554 | 554 |
| Charges related to legal matters, net | 8,057 | — | — | — | 8,057 |
| Other operating income | (1,298) | — | — | — | (1,298) |
| Operating income (loss) | $123,078 | $54,856 | $9,336 | $(57,501) | $129,769 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Amneal Pharmaceuticals, Inc.'s specialty — acquisition costs?
- Amneal Pharmaceuticals, Inc. (AMRX) reported specialty — acquisition costs of $0 in Q2 2026.
- What does specialty — acquisition costs mean?
- Non-recurring expenses related to the identification, due diligence, and integration of acquired businesses or product lines into the specialty segment. Tracking these costs helps investors understand the financial impact of inorganic growth strategies.
Ask your AI about Amneal Pharmaceuticals, Inc.'s specialty — acquisition costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude